Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Melanoma 20Neoplasms 13Breast Neoplasms 11Pancreatic Neoplasms 9Lung Neoplasms 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Neoplasm Metastasis 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Prostatic Neoplasms 4Hodgkin Disease 4Glioblastoma 4Carcinoma, Transitional Cell 4Carcinoma 4Uterine Cervical Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Adenocarcinoma 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Squamous Cell 2Mesothelioma 2

Interventions

pembrolizumab 1Taxes 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Staging IV NSCLC × pembrolizumab × Clear all
NCT04094909 2020-02-07

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Unknown
186 enrolled
Thoracic

Staging IV NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡